{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:58:56Z","timestamp":1790369936422,"version":"4.1.0"},"reference-count":77,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/ http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Bispecific antibodies (BsAbs) bind simultaneously to an antigen on the surface of multiple myeloma (MM) cells and to CD3 on the surface of T cells. This engagement leads to T-cell activation and degranulation, releasing perforin and granzymes, followed by the killing of the MM cell. Off-the-shelf available BsAbs targeting BCMA, GPRC5D, and FcRH5 have pronounced antitumor activity in heavily pretreated MM with cytokine-release syndrome, neutropenia, and infections as the most common side effects. To further improve clinical outcomes, BsAb-based combinations are being evaluated in earlier treatment lines, including newly diagnosed MM. Notably, the MajesTEC-3 trial established the combination of teclistamab and daratumumab as a new standard-of-care for relapsed\/refractory MM as early as first relapse. The most common mechanism underlying acquired resistance to BsAbs is loss of antigen expression; therefore, dual-targeting strategies (combination of BsAbs targeting different tumor antigens or trispecific antibodies) are being intensively investigated to enhance the depth and duration of response.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000847","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:00:43Z","timestamp":1790366443000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["T-Cell Redirecting Antibodies for the Treatment of Multiple Myeloma: Off-the-Shelf T-Cell Immunity"],"prefix":"10.1097","volume":"32","author":[{"given":"Niels W.C.J.","family":"van de Donk","sequence":"first","affiliation":[{"name":"Department of Hematology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Febe","family":"Smits","sequence":"additional","affiliation":[{"name":"Department of Hematology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"O\u2019Neill","sequence":"additional","affiliation":[{"name":"Department of Hematology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos","family":"Hoekman","sequence":"additional","affiliation":[{"name":"Department of Hematology"},{"name":"Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy","family":"Kruyswijk","sequence":"additional","affiliation":[{"name":"Department of Hematology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena R.","family":"Baglio","sequence":"additional","affiliation":[{"name":"Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Zweegman","sequence":"additional","affiliation":[{"name":"Department of Hematology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte L.B.M.","family":"Korst","sequence":"additional","affiliation":[{"name":"Department of Hematology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9]]},"reference":[{"key":"R1-20260925","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"van de Donk","year":"2021","journal-title":"Lancet"},{"key":"R2-20260925","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","article-title":"CD38 antibodies in multiple myeloma: back to the future","volume":"131","author":"van de Donk","year":"2018","journal-title":"Blood"},{"key":"R3-20260925","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0140-6736(23)00521-4","article-title":"T-cell-engaging bispecific antibodies in cancer","volume":"402","author":"van de Donk","year":"2023","journal-title":"Lancet"},{"key":"R4-20260925","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1158\/1078-0432.CCR-19-2299","article-title":"Preclinical activity of JNJ-7957, a Novel BCMA\u00d7CD3 bispecific antibody for the treatment of multiple myeloma, is potentiated by daratumumab","volume":"26","author":"Frerichs","year":"2020","journal-title":"Clin Cancer Res"},{"key":"R5-20260925","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/bloodadvances.2020003805","article-title":"Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma","volume":"5","author":"Verkleij","year":"2021","journal-title":"Blood Adv"},{"key":"R6-20260925","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1182\/bloodadvances.2023011658","article-title":"Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation","volume":"8","author":"Frerichs","year":"2024","journal-title":"Blood Adv"},{"key":"R7-20260925","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood.2025029572","article-title":"Selective depletion of B-cell subsets underlies increased risk of infection in MM patients treated with anti-BCMA versus GPRC5D bsAbs","volume":"147","author":"Jelinek","year":"2025","journal-title":"Blood"},{"issue":"suppl 16","key":"R8-20260925","doi-asserted-by":"crossref","first-page":"7540","DOI":"10.1200\/JCO.2024.42.16_suppl.7540","article-title":"Long-term follow-up from the phase 1\/2 MajesTEC-1 trial of teclistamab in patients with relapsed\/refractory multiple myeloma","volume":"42","author":"Garfall","year":"2024","journal-title":"J Clin Oncol"},{"issue":"suppl 16","key":"R9-20260925","doi-asserted-by":"crossref","first-page":"8011","DOI":"10.1200\/JCO.2023.41.16_suppl.8011","article-title":"Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"van de Donk","year":"2023","journal-title":"J Clin Oncol"},{"key":"R10-20260925","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1002\/hem3.136","article-title":"Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: update from the MagnetisMM-3 study","volume":"8","author":"Tomasson","year":"2024","journal-title":"HemaSphere"},{"key":"R11-20260925","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1182\/blood-2024-199733","article-title":"Linvoseltamab in patients with relapsed\/refractory multiple myeloma: longer follow-up and selected high-risk subgroup analyses of the linker-MM1 study","volume":"144","author":"Shah","year":"2024","journal-title":"Blood"},{"key":"R12-20260925","doi-asserted-by":"crossref","first-page":"e269","DOI":"10.1016\/S2352-3026(24)00385-5","article-title":"Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study","volume":"12","author":"Chari","year":"2025","journal-title":"Lancet Haematol"},{"key":"R13-20260925","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"R14-20260925","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 Magnetis MM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"key":"R15-20260925","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.24.01008","article-title":"Linvoseltamab for treatment of relapsed\/refractory multiple myeloma","volume":"42","author":"Bumma","year":"2024","journal-title":"J Clin Oncol"},{"key":"R16-20260925","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41408-024-01160-1","article-title":"Impact of COVID-19 on outcomes with teclistamab in patients with relapsed\/refractory multiple myeloma in the phase 1\/2 MajesTEC-1 study","volume":"14","author":"van de Donk","year":"2024","journal-title":"Blood Cancer J"},{"key":"R17-20260925","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1200\/JCO.22.01504","article-title":"A phase I first-in-human study of ABBV-383, a B-cell maturation antigen \u00d7 CD3 bispecific T-cell redirecting antibody, in patients with relapsed\/refractory multiple myeloma","volume":"40","author":"D\u2019Souza","year":"2022","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"R18-20260925","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1182\/blood-2023-182345","article-title":"Results from the completed dose escalation portion of the phase 1 study of HPN217, a half-life extended tri-specific T cell activating construct (TriTAC\u00ae) targeting B cell maturation antigen (BCMA) for relapsed\/refractory multiple myeloma (MM)","volume":"142","author":"Madan","year":"2023","journal-title":"Blood"},{"key":"R19-20260925","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.clml.2024.05.003","article-title":"Clinical management of patients with relapsed\/refractory multiple myeloma treated with talquetamab","volume":"24","author":"Chari","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"suppl 1","key":"R20-20260925","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1182\/blood-2025-91","article-title":"A first-in-human, phase I\/II, open-label, multicenter, dose escalation and expansion study of lbl-034, a conditionally activated bispecific antibody targeting GPRC5D and CD3 with a 2:1 format, in patients with relapsed\/refractory multiple myeloma","volume":"146","author":"Dou","year":"2025","journal-title":"Blood"},{"key":"R21-20260925","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S2152-2650(23)01572-0","article-title":"OA-05 Efficacy of forimtamig, a GPRC5DxCD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM): analysis of patient and disease-related factors associated with responses","volume":"23","author":"Harrison","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R22-20260925","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ccell.2017.02.001","article-title":"Membrane-proximal epitope facilitates efficient T cell synapse formation by anti-FcRH5\/CD3 and is a Requirement for myeloma cell killing","volume":"31","author":"Li","year":"2017","journal-title":"Cancer Cell"},{"issue":"suppl 1","key":"R23-20260925","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1182\/blood-2024-199542","article-title":"Cevostamab in Patients with Heavily Pretreated Relapsed\/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study Demonstrate Clinically Meaningful Activity and Manageable Safety and Inform the Doses and Regimen for Combination Studies","volume":"144","author":"Richter","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"R24-20260925","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1182\/blood-2025-700","article-title":"Subcutaneous cevostamab demonstrates manageable safety and clinically meaningful activity in Relapsed\/Refractory multiple myeloma (RRMM): First results from the Phase Ib CAMMA 3 study","volume":"146","author":"Ho","year":"2025","journal-title":"Blood"},{"key":"R25-20260925","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/S1470-2045(24)00043-3","article-title":"International Myeloma Working Group Immunotherapy Committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma","volume":"25","author":"Rodriguez-Otero","year":"2024","journal-title":"Lancet Oncol"},{"key":"R26-20260925","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1002\/cncr.34756","article-title":"Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed\/refractory multiple myeloma","volume":"129","author":"Martin","year":"2023","journal-title":"Cancer"},{"key":"R27-20260925","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"R28-20260925","doi-asserted-by":"crossref","first-page":"e71276","DOI":"10.1002\/cam4.71276","article-title":"Characterization and management of cytokine release syndrome from the MonumenTAL-1 study of talquetamab in patients with relapsed\/refractory multiple myeloma","volume":"14","author":"van de Donk","year":"2025","journal-title":"Cancer Med"},{"issue":"suppl 16","key":"R29-20260925","doi-asserted-by":"crossref","first-page":"7517","DOI":"10.1200\/JCO.2024.42.16_suppl.7517","article-title":"Longer-term follow-up of patients (pts) receiving prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) in the phase 1\/2 MajesTEC-1 study of teclistamab in relapsed\/refractory multiple myeloma (RRMM)","volume":"42","author":"Donk","year":"2024","journal-title":"J Clin Oncol"},{"key":"R30-20260925","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1002\/hem3.132","article-title":"Prophylactic tocilizumab reduces the incidence of cytokine release syndrome in relapsed\/refractory myeloma patients treated with teclistamab: Implications for outpatient step-up dosing","volume":"8","author":"Korst","year":"2024","journal-title":"Hemasphere"},{"key":"R31-20260925","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/s41408-023-00963-y","article-title":"Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: a single-center experience","volume":"13","author":"Scott","year":"2023","journal-title":"Blood Cancer J"},{"key":"R32-20260925","doi-asserted-by":"crossref","first-page":"4979","DOI":"10.1182\/bloodadvances.2025016911","article-title":"Tocilizumab prophylaxis for patients with multiple myeloma treated with bispecific antibodies","volume":"9","author":"Kowalski","year":"2025","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"R33-20260925","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1182\/blood-2025-247","article-title":"Ententamig plus pomalidomide-dexamethasone combination therapy in relapsed or refractory multiple myeloma: a phase 1b dose-escalation and safety expansion study","volume":"146","author":"Voorhees","year":"2025","journal-title":"Blood"},{"key":"R34-20260925","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.cmi.2024.02.023","article-title":"Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study","volume":"30","author":"Jourdes","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"R35-20260925","doi-asserted-by":"crossref","first-page":"5752","DOI":"10.1182\/bloodadvances.2025016613","article-title":"Infections and parameters of humoral immunity with talquetamab in relapsed\/refractory multiple myeloma in MonumenTAL-1","volume":"9","author":"Schinke","year":"2025","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"R36-20260925","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1182\/blood-2025-252","article-title":"Tumor clearance, T-cell fitness, and minimal residual disease (MRD) outcomes in patients with relapsed\/refractory multiple myeloma (RRMM) treated with cevostamab plus pomalidomide and dexamethasone: Biomarker analyses from CAMMA 1 Arm B","volume":"146","author":"Harrison","year":"2025","journal-title":"Blood"},{"key":"R37-20260925","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1158\/1078-0432.CCR-23-3333","article-title":"T-cell characteristics impact response and resistance to T-cell-redirecting bispecific antibodies in multiple myeloma","volume":"30","author":"Verkleij","year":"2024","journal-title":"Clin Cancer Res"},{"key":"R38-20260925","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/2643-3230.BCD-23-0049","article-title":"IVIg use associated with ten-fold reduction of serious infections in multiple myeloma patients treated with anti-BCMA bispecific antibodies","volume":"4","author":"Lancman","year":"2023","journal-title":"Blood Cancer Discov"},{"key":"R39-20260925","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2643-3230.BCD-24-0124","article-title":"T-cell-redirecting bispecific antibodies in multiple myeloma: optimal dosing schedule and duration of treatment","volume":"5","author":"van de Donk","year":"2024","journal-title":"Blood Cancer Discov"},{"issue":"supple 1","key":"R40-20260925","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1182\/blood-2023-177735","article-title":"A phase 2, single-arm, non-inferiority study of limited-duration teclistamab for relapsed and refractory multiple myeloma (LimiTec)","volume":"142","author":"Razzo","year":"2023","journal-title":"Blood"},{"key":"R41-20260925","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17213569","article-title":"Teclistamab dosing strategies in relapsed\/refractory myeloma: a real-world comparison of weekly and biweekly versus fixed intervals","volume":"17","author":"Snyder","year":"2025","journal-title":"Cancers"},{"key":"R42-20260925","first-page":"20","article-title":"Characterization of dysgeusia and xerostomia in patients with multiple myeloma treated with the T-cell redirecting GPRC5D bispecific antibody talquetamab","volume":"32","author":"Laheij","year":"2023","journal-title":"Support Care Cancer"},{"key":"R43-20260925","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-targeted CAR T cells for myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N Engl J Med"},{"key":"R44-20260925","doi-asserted-by":"crossref","first-page":"e693","DOI":"10.1016\/S2352-3026(24)00186-8","article-title":"Mechanisms of resistance against T-cell engaging bispecific antibodies in multiple myeloma: implications for novel treatment strategies","volume":"11","author":"van de Donk","year":"2024","journal-title":"Lancet Haematol"},{"key":"R45-20260925","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1182\/blood.2023022823","article-title":"Correlation of immune fitness with response to teclistamab in relapsed\/refractory multiple myeloma in the MajesTEC-1 study","volume":"144","author":"Cortes-Selva","year":"2024","journal-title":"Blood"},{"key":"R46-20260925","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1038\/leu.2017.41","article-title":"Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL","volume":"31","author":"Duell","year":"2017","journal-title":"Leukemia"},{"issue":"suppl 1","key":"R47-20260925","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1182\/blood-2025-1030","article-title":"Antigen-dependent clonal sweep with sequential or combinatory anti-myeloma T cell engagers","volume":"146","author":"Lee","year":"2025","journal-title":"Blood"},{"key":"R48-20260925","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1182\/bloodadvances.2021004418","article-title":"Single- and double-hit events in genes encoding immune targets before and after T cell-engaging antibody therapy in MM","volume":"5","author":"Truger","year":"2021","journal-title":"Blood Adv"},{"key":"R49-20260925","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat Med"},{"key":"R50-20260925","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/s43018-023-00625-9","article-title":"Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation","volume":"4","author":"Derrien","year":"2023","journal-title":"Nat Cancer"},{"issue":"suppl 1","key":"R51-20260925","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1182\/blood-2023-181607","article-title":"Functional characterization of GPRC5D alteration and Its impact on talquetamab resistance in relapsed\/ refractory multiple myeloma","volume":"142","author":"Han","year":"2023","journal-title":"Blood"},{"key":"R52-20260925","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1182\/blood-2024-204929","article-title":"Combined PD-1 and Tim-3 blockade improves the in vitro anti-myeloma activity of T cells of patients on talquetamab","volume":"144","author":"Mouhieddine","year":"2024","journal-title":"Blood"},{"key":"R53-20260925","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s40265-017-0689-1","article-title":"Immunomodulatory drugs in multiple myeloma: mechanisms of action and clinical experience","volume":"77","author":"Holstein","year":"2017","journal-title":"Drugs"},{"issue":"suppl 1","key":"R54-20260925","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2024-205608","article-title":"Phase 3 study of teclistamab (Tec) in combination with lenalidomide (Len) and Tec alone versus Len alone in newly diagnosed multiple myeloma (NDMM) as maintenance therapy following autologous stem cell transplantation (ASCT): safety run-in (SRI) results from the majestec-4\/EMN30 trial","volume":"144","author":"Zamagni","year":"2024","journal-title":"Blood"},{"key":"R55-20260925","doi-asserted-by":"crossref","first-page":"921","DOI":"10.2147\/OTT.S398118","article-title":"The role of CELMoD agents in multiple myeloma","volume":"18","author":"van de Donk","year":"2025","journal-title":"Onco Targets Ther"},{"key":"R56-20260925","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1021\/acs.jmedchem.6b01921","article-title":"A cereblon modulator (CC-220) with improved degradation of ikaros and aiolos","volume":"61","author":"Matyskiela","year":"2018","journal-title":"J Med Chem"},{"issue":"suppl 1","key":"R57-20260925","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1182\/blood-2025-100","article-title":"Safety and efficacy of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma: Results from the phase 1b MagnetisMM-30 trial","volume":"146","author":"Suvannasankha","year":"2025","journal-title":"Blood"},{"issue":"suppl 1","key":"R58-20260925","doi-asserted-by":"crossref","first-page":"5835","DOI":"10.1182\/blood-2025-5835","article-title":"Phase I\/II study of mezigdomide and elranatamab for relapsed\/refractory multiple myeloma patients (MELT-MM): Initial results from part 1","volume":"146","author":"Byun","year":"2025","journal-title":"Blood"},{"key":"R59-20260925","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"R60-20260925","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1182\/blood.2025029360","article-title":"Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study","volume":"146","author":"Chari","year":"2025","journal-title":"Blood"},{"issue":"suppl 16","key":"R61-20260925","doi-asserted-by":"crossref","first-page":"8032","DOI":"10.1200\/JCO.2022.40.16_suppl.8032","article-title":"A novel, immunotherapy-based approach for the treatment of relapsed\/refractory multiple myeloma (RRMM): Updated phase 1b results for daratumumab in combination with teclistamab (a BCMA x CD3 bispecific antibody)","volume":"40","author":"Rodr\u00edguez-Otero","year":"2022","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"R62-20260925","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1182\/blood-2025-701","article-title":"Safety and efficacy of talquetamab + teclistamab in patients with Relapsed\/Refractory multiple myeloma from Phase 1b of redirectt-1: results with an extended median follow-up of 3 years","volume":"146","author":"Mateos","year":"2025","journal-title":"Blood"},{"key":"R63-20260925","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1056\/NEJMoa2514752","article-title":"Dual targeting of extramedullary myeloma with talquetamab and teclistamab","volume":"394","author":"Kumar","year":"2025","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"R64-20260925","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1182\/blood-2025-4042","article-title":"Updated efficacy and safety results of JNJ-5322, a novel, next-generation BCMA\u00d7GPRC5D\u00d7CD3 trispecific antibody, in patients with Relapsed\/Refractory multiple myeloma","volume":"146","author":"Krishnan","year":"2025","journal-title":"Blood"},{"key":"R65-20260925","doi-asserted-by":"crossref","first-page":"7505","DOI":"10.1200\/JCO.2025.43.16_suppl.7505","article-title":"First-in-human study of JNJ-79635322 (JNJ-5322), a novel, next-generation trispecific antibody (TsAb), in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): Initial phase 1 results","volume":"43","author":"van de Donk","year":"2025","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"R66-20260925","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.1182\/blood-2024-199423","article-title":"MBS314, a G protein-coupled receptor family C group 5 member D (GPRC5D) x B-Cell maturation antigen (BCMA) x CD3 trispecific antibody, in relapsed and\/or refractory multiple myeloma (RRMM): preliminary results from a Phase \u2160, first-in-human, open-label, dose escalation study","volume":"144","author":"An","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"R67-20260925","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1182\/blood-2025-702","article-title":"Initial Results of the first-in-human Phase 1 study of IBI3003, a novel trispecific antibody targeting GPRC5D, BCMA, and CD3, in patients with relapsed or refractory multiple myeloma","volume":"146","author":"Li","year":"2025","journal-title":"Blood"},{"key":"R68-20260925","doi-asserted-by":"crossref","first-page":"e70260","DOI":"10.1002\/hem3.70260","article-title":"Sequencing BCMA- and GPRC5D-targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network","volume":"9","author":"van de Donk","year":"2025","journal-title":"Hemasphere"},{"key":"R69-20260925","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1182\/bloodadvances.2019000600","article-title":"T-cell phenotypes associated with effective CAR T-cell therapy in postinduction versus relapsed multiple myeloma","volume":"3","author":"Garfall","year":"2019","journal-title":"Blood Adv"},{"key":"R70-20260925","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1056\/NEJMoa2514663","article-title":"Teclistamab plus daratumumab in relapsed or refractory multiple myeloma","volume":"394","author":"Costa","year":"2025","journal-title":"N Engl J Med"},{"key":"R71-20260925","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/s41571-024-00927-6","article-title":"BCMA-directed therapy for early relapsed and\/or refractory multiple myeloma","volume":"21","author":"van de Donk","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"suppl 1","key":"R72-20260925","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1182\/blood-2024-206003","article-title":"Phase 2 study of teclistamab-based induction regimens in patients with transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): results from the GMMG-HD10\/DSMM-XX (MajesTEC-5) trial","volume":"144","author":"Raab","year":"2024","journal-title":"Blood"},{"issue":"suppl 16","key":"R73-20260925","doi-asserted-by":"crossref","first-page":"7506","DOI":"10.1200\/JCO.2024.42.16_suppl.7506","article-title":"Safety results from the phase 3 MajesTEC-7 study in patients (pts) with transplant ineligible\/not intended newly diagnosed multiple myeloma (NDMM)","volume":"42","author":"Touzeau","year":"2024","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"R74-20260925","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1182\/blood-2025-367","article-title":"A phase 2 Study of teclistamab in combination with daratumumab in elderly patients with newly diagnosed multiple myeloma: the IFM2021-01 teclille trial, cohort a","volume":"146","author":"Manier","year":"2025","journal-title":"Blood"},{"issue":"suppl 16","key":"R75-20260925","doi-asserted-by":"crossref","first-page":"TPS8065","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8065","article-title":"MagnetisMM-6: An open-label, multicenter, randomized phase 3 study of elranatamab + daratumumab + lenalidomide (EDR) versus daratumumab + lenalidomide + dexamethasone (DRd) in transplant-ineligible (TI) patients with newly diagnosed multiple myeloma (NDMM)","volume":"41","author":"Grosicki","year":"2023","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"R76-20260925","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2025-697","article-title":"Safety and efficacy of linvoseltamab as a simplified monotherapy first-line regimen in NDMM: initial results from the window of opportunity phase 1\/2 LINKER-MM4 trial","volume":"146","author":"Orlowski","year":"2025","journal-title":"Blood"},{"issue":"suppl 1","key":"R77-20260925","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1182\/blood-2025-248","article-title":"A phase 2 trial of abbreviated fixed-duration (Default 4 Cycles) linvoseltamab immuno-consolidation to deepen responses post newly diagnosed multiple myeloma combination therapy for minimal residual disease positivity (the IMMUNOPLANT Study)","volume":"146","author":"Kazandjian","year":"2025","journal-title":"Blood"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/PPO.0000000000000847","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:00:53Z","timestamp":1790366453000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/PPO.0000000000000847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":77,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000847","relation":{},"ISSN":["1540-336X","1528-9117"],"issn-type":[{"value":"1540-336X","type":"electronic"},{"value":"1528-9117","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"2026-01-30","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-12","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}